Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Stereospecific Activation of Cardiac ATP-Sensitive K+Channels by Epoxyeicosatrienoic Acids: A Structural Determinant Study

Tong Lu, Mike VanRollins and Hon-Chi Lee
Molecular Pharmacology November 2002, 62 (5) 1076-1083; DOI: https://doi.org/10.1124/mol.62.5.1076
Tong Lu
Departments of 1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike VanRollins
Departments of 1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hon-Chi Lee
Departments of 1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The heart is richly endowed with KATP channels, which function as biological sensors, regulating membrane potentials and electrical excitability in response to metabolic alterations. We recently reported that the cytochrome P450 metabolites of arachidonic acid, epoxyeicosatrienoic acids (EETs), potently activate cardiac KATP channels by reducing channel sensitivity to ATP. In the present study, we further demonstrate that 11(S),12(R)-EET activated the cardiac KATP channels with an EC50 of 39.5 nM, whereas 11(R),12(S)-EET was totally inactive. In addition, 11(S),12(R)-EET but not 11(R),12(S)-EET hyperpolarized the resting membrane potentials and shortened the duration of cardiomyocyte action potentials. By studying homologs and analogs of 11,12-EET, we also found that all four EET regioisomers are equipotent activators of the KATP channels, reducing the ATP sensitivity by more than 10-fold; however, neither altered chain length, double bond number, epoxide position, nor methylation of the carboxyl group affected channel inhibitions by ATP. All the fatty epoxides studied are potent KATP channel activators, but the ω-3 homolog was particularly potent, reducing ATP sensitivity 27-fold. Together, the results indicate that the presence of an epoxide group in a particular three-dimensional configuration is a critical determinant for KATP channel activation, and its effect is augmented by a double bond at ω-3 position. The results also suggest that fatty epoxides are important modulators of cardiac electrical excitability.

ATP-sensitive K+ (KATP) channels are densely populated in the heart and play an important role in regulating the membrane potential in response to intracellular metabolic oscillations (Yokoshiki et al., 1998). KATPchannels are thought to be activated during cardiac ischemia and hypoxia when cytoplasmic ATP is depleted, which would lead to shortened cardiac action potentials, reducing Ca2+ influx and minimizing intracellular Ca2+ overload (Noma, 1983; Nichols and Lederer, 1990; Tung and Kurachi, 1991). However, the function of the cardiac KATP channels under normal conditions is not well understood.

Arachidonic acid is an important precursor of many bioactive lipids (Brash, 2001; Funk, 2001; Roman, 2002). The cytochrome P450 (P450) epoxygenase metabolites of arachidonate have emerged as an important source of signaling agents (Zeldin, 2001; Roman, 2002). The CYP2J epoxygenases, abundant in human and rat hearts (Zeldin, 2001), convert arachidonic acid into four epoxyeicosatrienoic acid (EET) regioisomers: 5,6-, 8,9-, 11,12-, and 14,15-EET, each of which can be formed as theR,S or S,R enantiomer (McGiff, 1991; Zeldin, 2001). EET products are endogenous constituents of rat cardiac tissue, occurring at 69 ± 7 ng of total EETs/g of heart (Wu et al., 1997). EETs can be further hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by epoxide hydrolase (Zeldin et al., 1993). In coronary vascular endothelial cells, inhibition of soluble epoxide hydrolase results in the accumulation of both chain elongation and chain shortened homologs of EET (Fang et al., 2001).

There is very limited information on the specific binding of EETs in cells and an EET receptor has not yet been identified. Most of the physiological effects of EETs do not appear to involve regio- or stereospecificity (Oltman et al., 1998; Lee et al., 1999; Lu et al., 2001b; Zhang et al., 2001). However, specific high affinity binding sites for 14,15-EET are present in U-937 cells, which may be associated with a receptor (Wong et al., 1997), and stereospecific effects of 11,12-EET have been reported on renal vascular tone and K+ channel activity (Zou et al., 1996). Nevertheless, stereospecific effects of EETs have not been previously demonstrated in cardiac tissue.

Recently, we reported that EETs potently activated the cardiac KATP channels by reducing channel sensitivity to ATP, allowing the channel to remain open in the presence of physiological concentrations of cytoplasmic ATP (5 mM) (Lu et al., 2001a). In the present study, we tried to determine whether EETs stereospecifically activated KATP channels and stereospecifically altered the membrane potentials of cardiac myocytes. In addition, to assess the role of other structural determinants, we examined the effects of various EET homologs and analogs on the KATP channel activity (Fig.1). Although epoxide stereochemistry was critical for KATP channel activation and membrane potential hyperpolarization, the position of the epoxide group and the presence of an anionic carboxylic group were not. These results suggest that endogenous EETs may activate cardiac KATPchannels by binding at specific sites in cardiomyocytes, thereby modulating cardiac electrophysiology.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Structures of 11,12-EET and its homologs/analogs.

Materials and Methods

Preparation of Single Ventricular Myocytes.

Ventricular myocytes were isolated from male Sprague-Dawley rats by enzymatic dissociation (Lee et al., 1999). Briefly, animals were anesthetized with methoxyfluorane and the hearts were rapidly excised. A modified Langendorff apparatus was used to perfuse hearts for 5 min at 37°C with nominally Ca2+-free Tyrode's solution containing 138 mM NaCl, 4.5 mM KCl, 0.5 mM MgCl2, 0.33 mM Na2HPO4, 5.5 mM glucose, 10 mM HEPES, and 0.1% (w/v) bovine serum albumin, adjusted to pH 7.4 with NaOH. The perfusate was switched to a nominally Ca2+-free Tyrode's solution containing 0.6 mg/ml collagenase (CLS-2, 347 units/mg; Worthington Chemicals, Freehold, NJ) for 10 min. The ventricle was transferred to a fresh 0.6 mg/ml collagenase solution, cut into small pieces (∼2 mm3) and incubated at room temperature (22°C) for another 5 min. Dissociated cells were filtered through a medium mesh, centrifuged, and used within 24 h while stored at 22°C in 70 mM KOH, 40 mM KCl, 50 mM l-glutamic acid, 20 mM taurine, 0.5 mM MgCl2, 1.0 mM K2HPO4, 0.5 mM EGTA, 10 mM HEPES, 5 mM creatine, 5 mM pyruvic acid, and 5 mM Na2ATP, adjusted to pH 7.38 with KOH.

Inside-Out Patch Clamp Recording.

Single KATP channel currents were recorded with an Axopatch 200B amplifier (Axon Instruments, Foster City, CA), filtered at 5 kHz (8-pole Bessel filter unit; Frequency Devices, Haverhill, MA) and digitized at 50 kHz (Digidata; Axon Instruments). Data were acquired, stored in a Pentium-based personal computer, and later analyzed off-line using pClamp 7.0 (Axon Instruments). The KATP channels were identified by measuring conductance and ATP sensitivity as described (Lu et al., 2001a) and channel opening probability was determined byPo=∑j=1N tjj/TN where P o is the single channel open probability, T is the duration of recording,tj is the time spent withj = 1,2,… N channel openings andN is the maximal number of simultaneous channel openings observed when the bath solution contained no ATP. Only membrane patches containing not more than 5 KATP channels were used for P o analysis. Channel detection levels were set according to channel amplitude and pClamp uses 50% of the channel amplitude as the threshold for detection between open and closed states. The detection levels were used to construct interlevel transition thresholds, and each threshold is halfway between its detection levels.

The patch pipettes (Corning 7056; Warner Instrument, Hamden, CT) were coated with Sylgard 184 (Dow Corning, Midland, MI) and had a typical tip resistance between 2 and 5 MΩ when filled with 140 mM KCl, 1.0 mM EGTA, 5 mM HEPES, 1.0 mM CaCl2, 1.0 mM MgCl2, pH to 7.4 with KOH. Isolated ventricular myocytes were placed in a 0.5-ml chamber, and positioned on the stage of an inverted microscope (Olympus, IX70, Japan) before being superfused at 2 ml/min with a solution containing 70 mM KCl, 70 mMl-aspartic acid monopotassium salt, 2 mM EGTA, 5 mM HEPES, 7 mM N-methyl-d-glucamine, pH to 7.35 with N-methyl-d-glucamine. To generate an ATP inhibition curve, various amounts of ATP were added to the perfusate. When high concentrations of ATP (>1 mM) were used, the pH was readjusted with KOH. Dose-response curves were fitted using a Hill equation of the following formPo=Po,max/[1+(S/EC50)H] where S represents the concentration of the chemical, EC50 is the concentration at half-maximal effect, and H is the Hill coefficient. Curve fittings were performed using Igor 3.16 software (WaveMetrics Inc., Lake Oswego, OR).

Whole Cell Current Clamp Recordings.

Action potentials in rat ventricular myocytes were recorded at 37°C using the whole cell current clamp technique. Action potentials were elicited using 1 nA stimuli at 0.5 Hz and pCLAMP software. The signals were recorded with an Axopatch 200B amplifier, filtered at 5 kHz, and digitized at 20 kHz. The effects of 11(R),12(S)-EET, 11(S),12(R)-EET, and 11(S),12(R)-EET plus glyburide on the resting membrane potential (RP), action potential amplitude, and action potential duration at 90% repolarization (APD90) were measured. For these measurements, the cells were superfused with a Ca2+ Tyrode's solution containing 138 mM NaCl, 4.5 mM KCl, 0.5 mM MgCl2, 1.8 mM CaCl2, 0.33 mM Na2HPO4, 5.5 mM glucose, 10 mM HEPES, pH adjusted to 7.4 with NaOH. The pipette solution contained 130 mM KCl, 1.0 mM EGTA, 10 mM HEPES, 1.0 mM MgCl2, 5 mM ATP, 1.0 mM GTP, 0.018 mM CaCl2 (∼200 nM free Ca2+), pH to 7.38 with KOH.

Materials.

All chemicals used were racemic mixtures unless mentioned otherwise. The 1-14C-labeled EET regioisomers, 13,14-EDT, 11,12-EEQ, and the 11,12-EET enantiomers were freshly synthesized as previously described (Zhang et al., 2001). Arachidonic acid was purchased from Nu-Chek-Prep (Elysian, MN). 11,12-EET methyl ester, 11,12-DHET, 12,13-leukotoxin, and linoleic acid were obtained from Cayman Chemical (Ann Arbor, MI). Lactobacillic acid was purchased from Matreya Inc. (State College, PA). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Arachidonic acid, EETs, 11,12-EET methyl ester, 12,13-leukotoxin, 13,14-EDT, linoleic acid, and lactobacillic acid were prepared in 100% ethanol (5 mM) and stored under nitrogen at −20°C. Glyburide was dissolved in dimethylsulfoxide and stored at −20°C. The chemical stocks were used at greater than or equal to 1:103 dilutions in the experiments, and the final concentrations of ethanol or dimethylsulfoxide were less than 0.1%.

Statistical Methods.

Data are presented as mean ± S.E.M. Student's t test or paired t test was used to compare data between two groups. One-way analysis of variance with Tukey's test was used to compare data from multiple groups using Sigma Stat 2.0 software (Jandel Co., San Rafael, CA). Statistical significance was assumed at p < 0.05.

Results

Because 5 μM 11,12-EET activates the KATPchannels by reducing the channel sensitivity to ATP (Lu et al., 2001a), we compared the effects of 5 μM of various EET homologs and analogs. The results on EET regioselectivity are shown in Fig.2. Figure 2A shows recordings of KATP channels at −60 mV in the presence of 1 mM cytoplasmic ATP, with or without 5 μM 5,6-, 8,9-, 11,12-, and 14,15-EET. ATP (1 mM) was used because it almost totally (99%) suppressed KATP channel activities. However, in the presence of 5 μM EETs, appreciable KATPchannel activity was evident. The KATP channelP o versus ATP concentration relationships in the presence and absence of 5 μM EET regioisomers are plotted in Fig. 2B. All EET regioisomers were potent in reducing ATP sensitivity and increased the ATP IC50 from 31.5 ± 7.3 (n = 7) to 306 ± 52 μM for 5,6-EET (n = 7, p < 0.05 versus control), to 315 ± 36 μM for 8,9-EET (n = 6,p < 0.05 versus control), to 366 ± 72 μM for 11,12-EET (n = 7, p < 0.05 versus control), to 498 ± 83 for 14,15-EET (n = 6,p < 0.05 versus control), and without significant changes in the Hill coefficient of 1 to 1.2. Thus, the position of the epoxide group was not critical for KATPactivation. The ATP IC50 values for the EETs in this study were two-fold lower than previously reported (Lu et al., 2001a). We believe this difference could be accounted for by the source of EETs. In our previous study, we obtained 11,12-EET from a commercial source, whereas in the present study, [1-14C]EETs were synthesized and the final concentrations were carefully checked by liquid scintillation techniques.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Effects of EET regioisomers on cardiac KATP channel activity. A, typical tracings of KATP channels recorded at a membrane potential of −60 mV with 1 mM cytoplasmic ATP in the absence or presence of 5 μM 5,6-, 8,9-, 11,12-, or 14,15-EET. B, normalizedP o-ATP concentration relationships showing the effects of no EET (open circles), 5 μM 5,6-EET (filled diamonds), 5 μM 8,9-EET (filled squares), 5 μM 11,12-EET (filled circles), and 5 μM 14,15-EET (filled triangles) on ATP inhibition of KATP channels. KATP currents were measured at −60 mV with varying cytoplasmic ATP concentrations. NormalizedP o was obtained by dividing the measuredP o with maximumP o observed at 10−7 M ATP.

EET homologs and analogs (Fig. 1) were also tested to delineate whether other structural groups were important for EET activation of the KATP channels (Fig.3). Arachidonate and 11,12-DHET, the respective precursor and product of 11,12-EET, had no effect on the KATP channel activity; the ATP IC50 remained at 43.7 ± 10.1 μM (n = 6, p = N.S. versus control) and 39.5 ± 11.3 μM (n = 7, p = N.S. versus control), respectively (Fig. 3A). These results suggest that EET activation of the KATP channels in cardiac myocytes are not due to nonspecific fatty acid effects. In contrast, the methyl ester of 11,12-EET produced an effect similar to that of unesterified 11,12-EET; the ATP IC50 was shifted to 453 ± 110 μM (n = 6, p = N.S. versus 11,12-EET), and the Hill coefficient (1.0) remained unaltered (Fig. 3B). Thus, the presence of the epoxide group but not that of the anionic carboxylic group is crucial for KATP channel activation.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Effects of 11,12-EET and its homologs/analogs on ATP inhibition of the cardiac KATP channel activity. Experiments were conducted and P o normalized as described in Fig. 2B. Normalized P o-ATP relationships showing the effects of the following compounds on ATP inhibition of KATP channels: in the absence (open circles) and presence (filled diamonds) of 5 μM arachidonic acid, 5 μM 11,12-DHET (filled triangles), and 5 μM 11,12-EET (filled circles) (A); in the absence (open circles) and presence (filled circles) of 5 μM 11,12-EET and 5 μM 11,12-EET methyl ester (filled squares) (B); in the absence (open circles) and presence (filled triangles) of 5 μM linoleic acid, 5 μM lactobacillic acid (filled diamonds), 5 μM 12,13-leukotoxin (filled squares), and 5 μM 11,12-EET (filled circles) (C); in the absence (open circles) and presence (filled circles) of 5 μM 11,12-EET, 5 μM 13,14-EDT (filled diamonds), and 5 μM 11,12-EEQ (filled triangles) (D). TheP o-ATP curve for 11,12-EET was reproduced in B, C, and D for comparison purposes.

EET homologs and analogs were also used to test the effects of chain length on KATP channel activation. 12,13-Leukotoxin (9E,12,13-cis-epoxy-18:1), an 18-carbon epoxide with two less double bonds than the EETs, activated the KATP channel and increased the ATP IC50 of the channel to 398 ± 79 μM (n = 6, p < 0.05 versus control), similar to those of EETs (Fig. 3C). In contrast, lactobacillic acid (cis-11,12-methylene 18:0), an analog of 12,13-leukotoxin, which contains a cis methylene ring instead of acis oxirane ring and no double bond, had no effect on the ATP IC50 (34.3 ± 13.1 μM,n = 7, p = N.S. versus control). Furthermore, the unsubstituted fatty acid analog, linoleic acid (9E,12E-18:2), had no effect on the KATP channel activation with ATP IC50 at 34.1 ± 12.5 μM (n= 6, p = N.S. versus control). These results confirmed that the epoxide group is critical for KATPchannel activation, whereas chain shortening by two carbons or reducing the number of double bonds did not alter the epoxide effect.

EET homologs and analogs were also used to test the effects of chain elongation or increasing the number of double bonds (Fig. 3D). 13,14-EDT is an 11,12-EET chain-elongation homolog with two additional carbons inserted at the COOH end. 11,12-EEQ is an ω-3 analog of 11,12-EET with an additional double bond between 17-C and 18-C (Fig.1). 13,14-EDT was as effective as 11,12-EET in reducing the KATP channel sensitivity to ATP; the IC50 shifted to 321 ± 64 μM (n = 6, p < 0.05 versus control;p = N.S. versus 11,12-EET). Surprisingly, 11,12-EEQ was more potent than 11,12-EET in reducing ATP sensitivity in the KATP channel; yet, although 11,12-EEQ shifted the IC50 to 1071 ± 261 μM (n= 5, p < 0.05 versus 11,12-EET), the Hill coefficient remained unaltered at 1.1. These results confirmed that small (2 carbon) changes in chain-length were not critical; however, an additional double bond at the ω-3 position enhanced the ability of the epoxide to activate the KATP channels.

To determine whether 11,12-EET stereospecifically activated KATP channels, we synthesized and tested both of the 11(R),12(S)-EET and 11(S),12(R)-EET enantiomers. Figure4A shows recordings of multiple KATP channels in the presence of 5 μM 11(S),12(R)-EET (left) and 11(R),12(S)-EET (right). In the presence of 1.0 mM cytoplasmic ATP, KATP channel activity was significantly enhanced by 11(S),12(R)-EET but not by 11(R),12(S)-EET. 11(S),12(R)-EET shifted the ATP inhibitory curve to the right. The IC50 of 329 ± 124 μM (n = 5, p < 0.05 versus control) and Hill coefficient of 1.2 matched that of racemic 11,12-EET. In contrast, 11(R),12(S)-EET had no effect; the IC50 remained at 32.3 ± 11.2 μM (n = 5, p = N.S. versus control;p < 0.05 versus11(S),12(R)-EET) (Fig. 4B). Thus, the three-dimensional presentation of the epoxide was critical for activating KATP channels.

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4

Stereospecific effect of 11,12-EET on KATP channel activity. Experiments were performed andP o normalized as described in Fig. 2B. A, current tracings of KATP channels in the presence of 5 μM 11(S),12(R)-EET (left) or 5 μM 11(R),12(S)-EET (right) and varying concentrations of ATP. B, relationships of normalizedP o plotted against cytoplasmic ATP concentrations in the absence (open circles) and presence (filled circles) of 5 μM 11(S),12(R)-EET or 5 μM 11(R),12(S)-EET (filled squares).n = 5 for both groups.

The potency of 11(S),12(R)-EET in activating KATP channels was estimated by measuring the EC50 for channel activation. Channel activity was determined at −60 mV and with 100 μM cytosolic ATP because submaximal (only 80%) KATP channel activity was inhibited under these conditions. 11(S),12(R)-EET dose dependently enhanced the KATP channel activities (Fig. 5A. left column), whereas, 11(R),12(S)-EET was inactive (Fig. 5A, right column). 11(S),12(R)-EET potently activates the KATP channel with an EC50 of 39.5 ± 12.4 nM (n = 5), and this was about 2-fold higher than that previously reported for 11,12-EET (Lu et al., 2001a). We believe the differences in the source of EETs may account for the difference in results. In contrast, 11(R),12(S)-EET did not change channel activity at any concentration tested (Fig. 5B).

Figure 5
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5

Dose-dependent effect of 11(S),12(R)-EET on KATPchannel activation. A, raw tracings of KATP channel currents were recorded at −60 mV with 0.1 mM ATP, 1 μM Ca2+, and in the presence of various concentrations of 11(S),12(R)-EET (left) and 11(R),12(S)-EET (right). B, 11(S),12(R)-EET activated cardiac KATP channel with an EC50 of 39.5 ± 12.4 nM (filled circles), whereas 11(R),12(S)-EET was totally inactive (filled squares). n = 5 for both groups.

To determine whether activation of the KATPchannel altered the membrane potential in whole cells, we examined the effects of the 11,12-EET enantiomers on action potentials recorded from isolated ventricular myocytes. One typical experiment is shown in Fig.6A. Group data are shown in Fig. 6, B and C. Superfusion of 5 μM 11(S),12(R)-EET hyperpolarized the RP from −79.3 ± 2.3 mV to −83.4 ± 2.6 mV (n = 8, p = 0.008) and shortened the APD90 from 41.6 ± 5.0 ms to 35.5 ± 4.8 ms (n = 8, p = 0.006). The amplitude of the action potential at baseline (104.1 ± 5.5 mV) was not changed by 11(S),12(R)-EET (102.2 ± 5.7 mV, n = 8, p = N.S.). Both the changes in RP and APD90 were blocked by 2 μM glyburide, suggesting that the 11(S),12(R)-EET effects were due to KATP channel activation (Fig. 6B). However, superfusion of 5 μM 11(R),12(S)-EET did not alter the RP (−84.5 ± 1.4 mV versus −83.5 ± 1.9 mV at baseline, n = 8, p = N.S.), the APD90 (42.7 ± 3.7 ms versus 42.2 ± 2.3 ms at baseline, n = 8, p = N.S.), or the action potential amplitude (101.6 ± 3.6 mV versus 101.0 ± 2.3 mV at baseline, n = 8,p = N.S.) (Fig. 6C). These results indicate that modulation of the cardiac action potential by 11,12-EET is stereospecific.

Figure 6
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6

Stereospecific effect of 11,12-EET on action potentials in isolated ventricular myocytes. A, action potentials were elicited from a single ventricular myocyte at 37°C using current clamp techniques with 5 mM ATP in the pipette. RP was hyperpolarized and APD90 was shortened on exposure to 5 μM 11(S),12(R)-EET and these effects were reversed by superfusion with 2 μM glyburide. 11(R),12(S)-EET had no effect. Scatter plots of group data are shown for 11(S),12(R)-EET (n = 8) (B) and for 11(R),12(S)-EET (n = 8) (C). The dark solid symbols and lines represent the means ± S.E.M. ∗, p < 0.05 versus baseline.

Discussion

In the present study, we have made four important and novel observations. First, we have demonstrated that activation of the KATP channel by EET involves absolute stereospecificity; only the 11(S),12(R)-EET enantiomer is active. Second, the epoxide group on EET is a critical structural determinant for activation of the KATPchannels. Third, an ω-3 double bond enhances the potency of the epoxide for KATP channel activation. Fourth, 11(S),12(R)-EET hyperpolarizes resting membrane potentials and shortens action potentials. These results suggest that endogenous EETs are specific activators of the cardiac KATP channels and may play an important role in regulating cardiac electrical excitability.

EETs regulate vital physiological functions including vasoreactivity (Campbell et al., 1996; Oltman et al., 1998; Zhang et al., 2001), inflammatory responses (Node et al., 1999), and cell proliferation (Fleming et al., 2001). Ion channels constitute an important class of EET effectors. In blood vessels, EETs cause vasodilation by activating the large conductance Ca2+-activated K+ (BK) channels and are putative endothelium-derived hyperpolarizing factors (Li and Campbell, 1997;Campbell and Harder, 1999). EETs are endogenous constituents of the heart (Wu et al., 1997). Moreover, EETs inhibit cardiac Na+ channels with the characteristics of a “modulated receptor” mechanism (Lee et al., 1999). The effects of EETs on the cardiac L-type Ca2+ channel are more variable, and both stimulation (Xiao et al., 1998) and inhibition (Chen et al., 1999) of channel activity have been observed. Recently, we reported that EETs are potent activators of the cardiac KATP channels, capable of activating the channel in the presence of 5 mM ATP, with an EC50 of 10−8 M (Lu et al., 2001a). The present study confirms that EETs are important KATP channel activators. We believe that the stereospecific effects of 11,12-EET on the KATP channel indicate specific interaction between 11,12-EET and the KATP channel protein or a channel-associated protein. It is likely that such specificity would entail a physiologically relevant and important function. The structurally specific requirements of the EET molecule for activating myocardial KATP channels is in sharp contrast to the relative lack of structural specificity for activating BK channels in coronary blood vessels (Zhang et al., 2001). EET-induced dilation and activation of BK channels in coronary microvessels did not show stereospecificity (Zhang et al., 2001). Also, 11,12-DHET is as potent as 11,12-EET in producing coronary vasorelaxation (Oltman et al., 1998) and in activating coronary BK channels (Lu et al., 2001b). To date, the stereospecificity of EET-induced vascular effects has been restricted to platelets (Fitzpatrick et al., 1986) and renal vessels (Katoh et al., 1991; Zou et al., 1996). Interestingly, 11(R),12(S)-EET rather than 11(S),12(R)-EET activates the BK channels in renal arteriolar smooth muscle cells (Zou et al., 1996), suggesting that stereospecificity is unique for different channel proteins.

Only limited data suggest EETs bind to specific receptors; however, binding of EETs to these sites have not yet been shown to alter cellular function (Wong et al., 1997). Fatty acid epoxides interact enantioselectively with many proteins including P450 epoxygenases and epoxide hydrolases (Orru and Faber, 1999). In the present study, the epoxide is a critical functional group in EETs, which activates KATP channels. Interaction between the oxirane ring and specific residues on the KATP channel conceivably requires precise configuration and orientation, thereby producing specific conformational changes in the channel protein leading to reduced ATP sensitivity and enhanced channel activity. Because substitution of the epoxide with diols or with a methylene ring abolished the KATP effects, the oxirane ring oxygen may facilitate critical hydrogen bond bridges or form an “intermediate” with nucleophilic groups of the KATP channel. However, formation of stable intermediates is unlikely because the effects of EETs on the KATP channel were rapidly reversible upon drug washout. Perhaps more importantly, the present findings exclude the possibility that EETs activate the KATP channels via a mechanism similar to that by phosphoinositides, in which the positively charged residues at the COOH terminus of the KATP channel are tethered by the electrostatic force of the anionic groups of the phospholipids at the cytoplasmic surface of the membrane, allowing the channel to be active (Fan and Makielski, 1997). Such a mechanism would require neither stereospecificity nor the presence of an epoxide group. Epoxide-based modulation of protein function has received increasing attention, and the utilization of epoxides in drug design has been shown to be effective in a number of compounds including a novel antitumor antibiotic, Rhizosin (Tolcher et al., 2000) and an angiogenesis inhibitor, TNP-470 (Stadler et al., 1999).

ω-3 fatty acids are essential fatty acids enriched in fish oils and have been shown to be cardioprotective from their anti-thrombosis, anti-atherosclerosis, anti-inflammatory, anti-vasoconstriction, and anti-arrhythmic effects (Connor, 2000). Kang and Leaf (2000) suggest that the suppression of fatal cardiac arrhythmias by ω-3 polyunsaturated fatty acids may involve the inhibition of the cardiac Na+ channels and L-type Ca2+ channels. The P450 epoxygenase metabolites of ω-3 fatty acids (EEQs) are potent vasodilators in coronary microvessels (Zhang et al., 2001). It is intriguing that the ω-3 fatty acid metabolite, 11,12-EEQ, is more potent than its ω-6 epoxide homolog, 11,12-EET, in activating the cardiac KATP channels. Whether this is related to the cardioprotective effects of ω-3 fatty acids is not known, but the physiological function of ω-3 fatty epoxides deserve further investigation. The ω-3 double bond, undoubtedly renders the hydrocarbon tail more rigid and nucleophilic. This appears to be the only structural determinant studied that augmented the ability of the fatty epoxide to activate KATP channels. Small changes in carbon chain length, lowered double bond numbers, altered epoxide positions, and the loss of the negative carboxylic charge did not affect the potency of the epoxide in reducing ATP sensitivity of the KATP channels in cardiac myocytes.

The physiologic importance of KATP channel activation by EET, in the presence of 5 mM ATP, is demonstrated by the hyperpolarization of resting membrane potentials and shortening of the action potentials. The effects of 11,12-EET were again stereospecific and completely reversed by glyburide, suggesting that these electrophysiological effects were mediated by the KATP channels. Whether these effects are cardioprotective or not is at present unclear, although there appears to be a greater effect on membrane potential than on APD90. Hyperpolarization of membrane potential would likely suppress abnormal automaticity and is therefore anti-arrhythmic in outcome. However, shortening of the action potential may promote reentry mechanisms of arrhythmia and may create dispersion of refractoriness, resulting in pro-arrhythmic effects. These issues will require detailed electrophysiological studies to resolve. Recently, blood in the coronary sinus of dog hearts showed significant increases in the levels of EETs and their metabolites during coronary occlusion and reperfusion (Nithipatikom et al., 2001). Under these conditions, EETs would accumulate in cardiomyocytes and ATP would be depleted, creating a situation in which significant activation of the KATP channels could occur. Indeed, using a KATP channel knockout mouse, the molecular basis of the ST segment elevation during acute myocardial infarction can be attributed to the activation of KATP channels (Li et al., 2000).

In conclusion, we have identified the structural determinants of EET for activation of the cardiac KATP channels and showed the effects of EET to be stereospecific. Our results indicate that EET can activate the KATP channels under physiological conditions and may serve to regulate cardiac electrical excitability.

Footnotes

    • Received February 21, 2002.
    • Accepted July 16, 2002.
  • This work was supported by a Merit Review Award from the Department of Veterans, by grants from the National Institute of Health (R01-HL-63754 to H. Lee and R01-HL-56670 to M. VanRollins) and from the American Heart Association (Grant-in-aid award 0051311Z to H. Lee and 96012380 to M. VanRollins).

Abbreviations

KATP channels
ATP-sensitive K+ channels
P450
cytochrome P450
EET
epoxyeicosatrienoic acid
DHET
dihydroxyeicosatrienoic acid
EDT
epoxydocosatrienoic acid
EEQ
epoxyeicosaquatraenoic acid
APD90
action potential duration at 90% repolarization
RP
resting membrane potential
BK channels
large conductance Ca2+-activated potassium channels
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Brash AR
    (2001) Arachidonic acid as a bioactive molecule. J Clin Investig 107:1339–1345.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Campbell WB,
    2. Gebremedhin D,
    3. Pratt PF, and
    4. Harder DR
    (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78:415–423.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Campbell WB and
    2. Harder DR
    (1999) Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 84:484–488.
    OpenUrlFREE Full Text
  4. ↵
    1. Chen J,
    2. Capdevila JH,
    3. Zeldin DC, and
    4. Rosenberg RL
    (1999) Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 55:288–295.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Connor WE
    (2000) Importance of n-3 fatty acids in health and disease. Am J Clin Nutr 71:171S–175S.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Fan Z and
    2. Makielski JC
    (1997) Anionic phospholipids activate ATP-sensitive potassium channels. J Biol Chem 272:5388–5395.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Fang X,
    2. Kaduce TL,
    3. Weintraub NL,
    4. Harmon S,
    5. Teesch LM,
    6. Morisseau C,
    7. Thompson DA,
    8. Hammock BD, and
    9. Spector AA
    (2001) Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 276:14867–14874.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Fitzpatrick FA,
    2. Ennis MD,
    3. Baze ME,
    4. Wynalda MA,
    5. McGee JE, and
    6. Liggett WF
    (1986) Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem 261:15334–15338.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Fleming I,
    2. Fisslthaler B,
    3. Michaelis UR,
    4. Kiss L,
    5. Popp R, and
    6. Busse R
    (2001) The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. Pfluegers Arch 442:511–518.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Funk CD
    (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (Wash DC) 294:1871–1875.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kang JX and
    2. Leaf A
    (2000) Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 71:202S–207S.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Katoh T,
    2. Takahashi K,
    3. Capdevila J,
    4. Karara A,
    5. Falck JR,
    6. Jacobson HR, and
    7. Badr KF
    (1991) Glomerular stereospecific synthesis and hemodynamic actions of 8,9-epoxyeicosatrienoic acid in rat kidney. Am J Physiol 261:F578–F586.
    OpenUrl
  13. ↵
    1. Lee H,
    2. Lu T,
    3. Weintraub NL,
    4. VanRollins M,
    5. Spector AA, and
    6. Shibata EF
    (1999) Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes. J Physiol 519:153–168.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Li PL and
    2. Campbell WB
    (1997) Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 80:877–884.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Li RA,
    2. Leppo M,
    3. Miki T,
    4. Seino S, and
    5. Marban E
    (2000) Molecular basis of electrocardiographic ST-segment elevation. Circ Res 87:837–839.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Lu T,
    2. Hoshi T,
    3. Weintraub NL,
    4. Spector AA, and
    5. Lee H
    (2001a) Activation of ATP-sensitive K+ channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J Physiol 537:811–827.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Lu T,
    2. Katakam PV,
    3. VanRollins M,
    4. Weintraub NL,
    5. Spector AA, and
    6. Lee H
    (2001b) Dihydroxyeicosatrienoic acids are potent activators of Ca2+-activated K+ channels in isolated rat coronary arterial myocytes. J Physiol 534:651–667.
    OpenUrlCrossRefPubMed
  18. ↵
    1. McGiff JC
    (1991) Cytochrome P-450 metabolism of arachidonic acid. Annu Rev Pharmacol Toxicol 31:339–369.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Nichols CG and
    2. Lederer WJ
    (1990) The regulation of ATP-sensitive K+ channel activity in intact and permeabilized rat ventricular myocytes. J Physiol 423:91–110.
    OpenUrlPubMed
  20. ↵
    1. Nithipatikom K,
    2. DiCamelli RF,
    3. Kohler S,
    4. Gumina RJ,
    5. Falck JR,
    6. Campbell WB, and
    7. Gross GJ
    (2001) Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs. Anal Biochem 292:115–124.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Node K,
    2. Huo Y,
    3. Ruan X,
    4. Yang B,
    5. Spiecker M,
    6. Ley K,
    7. Zeldin DC, and
    8. Liao JK
    (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science (Wash DC) 285:1276–1279.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Noma A
    (1983) ATP-regulated K+ channels in cardiac muscle. Nature (Lond) 305:147–148.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Oltman CL,
    2. Weintraub NL,
    3. VanRollins M, and
    4. Dellsperger KC
    (1998) Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 83:932–939.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Orru RV and
    2. Faber K
    (1999) Stereoselectivities of microbial epoxide hydrolases. Curr Opin Chem Biol 3:16–21.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Roman RJ
    (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131–185.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Stadler WM,
    2. Kuzel T,
    3. Shapiro C,
    4. Sosman J,
    5. Clark J, and
    6. Vogelzang NJ
    (1999) Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 17:2541–2545.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Tolcher AW,
    2. Aylesworth C,
    3. Rizzo J,
    4. Izbicka E,
    5. Campbell E,
    6. Kuhn J,
    7. Weiss G,
    8. Von Hoff DD, and
    9. Rowinsky EK
    (2000) A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 11:333–338.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Tung RT and
    2. Kurachi Y
    (1991) On the mechanism of nucleotide diphosphate activation of the ATP- sensitive K+ channel in ventricular cell of guinea-pig. J Physiol 437:239–256.
    OpenUrlPubMed
  29. ↵
    1. Wong PY,
    2. Lai PS,
    3. Shen SY,
    4. Belosludtsev YY, and
    5. Falck JR
    (1997) Post-receptor signal transduction and regulation of 14(R), 15(S)- epoxyeicosatrienoic acid (14,15-EET) binding in U-937 cells. J Lipid Mediat Cell Signal 16:155–169.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Wu S,
    2. Chen W,
    3. Murphy E,
    4. Gabel S,
    5. Tomer KB,
    6. Foley J,
    7. Steenberger C,
    8. Falck JR,
    9. Moomaw CR, and
    10. Zeldin DC
    (1997) Molecular cloning, expression and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272:12551–12559.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Xiao YF,
    2. Huang L, and
    3. Morgan JP
    (1998) Cytochrome P450: a novel system modulating Ca2+ channels and contraction in mammalian heart cells. J Physiol 508:777–792.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Yokoshiki H,
    2. Sunagawa M,
    3. Seki T, and
    4. Sperelakis N
    (1998) ATP-sensitive K+ channels in pancreatic, cardiac and vascular smooth muscle cells. Am J Physiol 274:C25–C37.
    OpenUrl
  33. ↵
    1. Zeldin DC
    (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276:36059–36062.
    OpenUrlFREE Full Text
  34. ↵
    1. Zeldin DC,
    2. Kobayashi J,
    3. Falck JR,
    4. Winder BS,
    5. Hammock BD,
    6. Snapper JR, and
    7. Capdevila JH
    (1993) Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem 268:6402–6407.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Zhang Y,
    2. Oltman CL,
    3. Lu T,
    4. Lee H,
    5. Dellsperger KC, and
    6. VanRollins M
    (2001) EET homologs potently dilate coronary microvessels and activate BKCa channels. Am J Physiol Heart Circ Physiol 280:H2430–H2440.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Zou AP,
    2. Fleming JT,
    3. Falck JR,
    4. Jacobs ER,
    5. Gebremedhin D,
    6. Harder DR, and
    7. Roman RJ
    (1996) Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K+-channel activity. Am J Physiol 270:F822–F832.
    OpenUrl
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 62 (5)
Molecular Pharmacology
Vol. 62, Issue 5
1 Nov 2002
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Stereospecific Activation of Cardiac ATP-Sensitive K+Channels by Epoxyeicosatrienoic Acids: A Structural Determinant Study
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Stereospecific Activation of Cardiac ATP-Sensitive K+Channels by Epoxyeicosatrienoic Acids: A Structural Determinant Study

Tong Lu, Mike VanRollins and Hon-Chi Lee
Molecular Pharmacology November 1, 2002, 62 (5) 1076-1083; DOI: https://doi.org/10.1124/mol.62.5.1076

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Stereospecific Activation of Cardiac ATP-Sensitive K+Channels by Epoxyeicosatrienoic Acids: A Structural Determinant Study

Tong Lu, Mike VanRollins and Hon-Chi Lee
Molecular Pharmacology November 1, 2002, 62 (5) 1076-1083; DOI: https://doi.org/10.1124/mol.62.5.1076
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Relapsed-Leukemia Model with NT5C2/PRPS1 Hotspot Mutations
  • The Binding Site for KCI807 in the Androgen Receptor
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics